Rockland Trust’s VanEck Biotech ETF BBH Stock Holding History

Rockland Trust’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,216	Closed	-$776K	–	160
2016 Q4	$776K	Buy	+7,216	New	+$785K	0.12%	94

Other funds holding BBH

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Rockland Trust's BBH Position: Q1 2017 in Review

Rockland Trust sold out of VanEck Biotech ETF (BBH) in Q1 2017, closing a stake of 7,216 shares — an estimated $776K sold.

Rockland Trust first reported a position in BBH in Q4 2016 and held it in 1 quarter. The position peaked at $776K in Q4 2016. 79 funds tracked by Wall St. Rank hold BBH as of Q1 2017.

Rockland Trust reported no remaining VanEck Biotech ETF position as of Q1 2017 after selling out during the quarter.
Rockland Trust sold 7,216 VanEck Biotech ETF shares in Q1 2017, an estimated $776K.
Rockland Trust first reported a position in VanEck Biotech ETF in Q4 2016 and held it in 1 quarter.
Rockland Trust's VanEck Biotech ETF position peaked at $776K in Q4 2016.
79 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2017.

Based on Rockland Trust's 13F filing for Q1 2017, filed 20 Apr 2017.